In conclusion, we developed a chimeric ADC targeting nectin-2, characterized its binding specificity, and examined its anti-tumor activity both in in vitro and in vivo models, which suggested that c12G1-DM1 is a potential therapeutic ADC that can be used to treat ovarian cancer. This evidence concerns the gene NECTIN2 and ovarian carcinoma.